Detailed product reference
Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.
Product overview
Pirespa is an antifibrotic for idiopathic pulmonary fibrosis, supplied in Japan as 200 mg tablets.
Read source section ↗Mechanism of action
Modulates fibrotic pathways and collagen production; its mechanism is not reducible to one proven clinical target.
Read source section ↗Japanese indications & eligibility
The Japanese indication is idiopathic pulmonary fibrosis; other fibrotic lung diseases require separate assessment.
Read source section ↗Administration & dose differences
Start 200 mg three times daily after meals and titrate toward 600 mg three times daily according to tolerance.
Read source section ↗Adverse effects & key risks
Important concerns include photosensitivity, GI intolerance, liver injury and blood-cell abnormalities.
Read source section ↗Contraindications & special populations
Ingredient hypersensitivity is contraindicated; assess liver/kidney function, pregnancy and dizziness-related safety.
Read source section ↗Drug interactions
CYP1A2 modifiers such as fluvoxamine/ciprofloxacin and changes in smoking affect exposure.
Read source section ↗Assessment & monitoring
Monitor liver function, blood counts, weight/nutrition and respiratory function.
Read source section ↗Storage & handling
Store at room temperature; the photo is the Japanese 200 mg blister.
Read source section ↗Sources & verification
Product checked ·
- PMDA electronic package insert ↗www.pmda.go.jp
Primary source for mechanism, indications, doses and risks; revision: 2022-03.
- Manufacturer information ↗med.shionogi.co.jp
Official product or related information; professional portals may require identity confirmation.
- Wikipedia: ingredient background ↗en.wikipedia.org
Background reference; Japanese approvals and administration are governed by PMDA sources.
